Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy
Authors:
- 30 September 2020
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 52 (1) , 281-290
Abstract
A perceived increased risk of bleeding is one of the most frequent reasons for withholding anticoagulation for stroke prevention in atrial fibrillation (AF). We previously conducted a randomized controlled trial of alert-based computerized decision support to increase prescription of anticoagulation in hospitalized patients with AF. To determine the clinical characteristics and outcomes of those patients whose inpatient health care providers received a computer alert, we analyzed all 248 patients in the alert group. Patients for whom providers elected to omit anticoagulation and provided a rationale of a perceived high risk of bleeding were compared with those who were not designated as high-risk. Perceived high risk of bleeding was the most common reason (77%) for omitting anticoagulation. Median HAS-BLED scores were similar in these patients compared with those who were not deemed to have an increased bleeding risk (3 vs. 3, p = 0.44). Despite being categorized as too high-risk for bleeding to receive antithrombotic therapy at the time of the alert, nearly 12% of these patients were ultimately prescribed anticoagulation by 90 days. The frequency of major and clinically-relevant non-major bleeding was similar between the groups. The frequency of death, myocardial infarction, stroke, or systemic embolic event was similar in both groups (10.2% vs. 12.4%, p = 0.59). In conclusion, a perceived high risk of bleeding was the most common reason for omission of anticoagulation in patients with AF after a computerized alert. Perceived high risk of bleeding was not reflected in a higher HAS-BLED score. Clinical trial registration: ClinicalTrials.gov Identifier: NCT02339493 https://clinicaltrials.gov/ct2/show/NCT02339493 Graphic Abstract In a randomized controlled trial of computerized decision support to increase prescription of antithrombotic therapy in hospitalized patients with atrial fibrillation (AF), a perceived high risk of bleeding was the most common reason (77%) for omitting antithrombotic therapy after an on-screen alert. Median HAS-BLED scores were similar in these patients compared with those who were not deemed to have an increased bleeding risk (3 vs. 3, p = 0.44). Despite being categorized as too high-risk for bleeding to receive antithrombotic therapy for stroke prevention at the time of the alert, nearly 12% of these patients were ultimately prescribed anticoagulation over the ensuing 90 days.Keywords
Funding Information
- Daiichi-Sankyo
This publication has 23 references indexed in Scilit:
- Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial FibrillationThe American Journal of Medicine, 2017
- Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AFEuropean Heart Journal, 2016
- Underutilization of Anticoagulation for Stroke Prevention in Atrial FibrillationJACC, 2016
- North American Thrombosis Forum, AF Action Initiative Consensus DocumentThe American Journal of Medicine, 2016
- Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients with Atrial FibrillationCardiovascular Therapeutics, 2015
- Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryAmerican Heart Journal, 2014
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillationEuropean Heart Journal, 2012
- Reinitiation of Anticoagulation After Warfarin-Associated Intracranial Hemorrhage and Mortality Risk: The Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) StudyCanadian Journal of Cardiology, 2011
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005